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Diabetic retinopathy (DR) screening is instrumental in preventing blindness, but faces a scaling
challenge as the number of diabetic patients rises. Risk stratification for the development of DR
may help optimize screening intervals to reduce costs while improving vision-related outcomes.
We created and validated two versions of a deep learning system (DLS) to predict the
development of mild-or-worse (“Mild+”) DR in diabetic patients undergoing DR screening. The
two versions used either three-fields or a single field of color fundus photographs (CFPs) as
input. The training set was derived from 575,431 eyes, of which 28,899 had known 2-year
outcome, and the remaining were used to augment the training process via multi-task learning.
Validation was performed on both an internal validation set (set A; 7,976 eyes; 3,678 with known
outcome) and an external validation set (set B; 4,762 eyes; 2,345 with known outcome).  For
predicting 2-year development of DR, the 3-field DLS had an area under the receiver operating
characteristic curve (AUC) of 0.79 (95%CI, 0.78-0.81) on validation set A. On validation set B
(which contained only a single field), the 1-field DLS’s AUC was 0.70 (95%CI, 0.67-0.74). The
DLS was prognostic even after adjusting for available risk factors (p<0.001). When added to the
risk factors, the 3-field DLS improved the AUC from 0.72 (95%CI, 0.68-0.76) to 0.81 (95%CI,
0.77-0.84) in validation set A, and the 1-field DLS improved the AUC from 0.62 (95%CI,
0.58-0.66) to 0.71 (95%CI, 0.68-0.75) in validation set B. The DLSs in this study identified
prognostic information for DR development from CFPs. This information is independent of and
more informative than the available risk factors.
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Research in context
Evidence before this study
A review of the current literature on predicting the progression risk of diabetic retinopathy (DR)
was conducted using Google Scholar, PubMed, Scopus, MEDLINE and Web of Science. The
search resulted in studies published in English until 15 June, 2020 using the keywords
“progression of diabetic retinopathy”, “predicting development of diabetic retinopathy”,
“predicting incident diabetic retinopathy”, “risk factors for diabetic retinopathy”, “diabetic
retinopathy screening programs”, “automated detection of diabetic retinopathy using fundus
photographs”, “artificial intelligence”, “machine learning” and “deep learning”. Although few
studies have investigated the risk of DR progression on fundus photographs using deep
learning, to our knowledge no study has reported automated risk stratification of developing DR
from no DR on fundus photographs or this prediction in combination with known risk factors.
Added value of this study
In this study, we created a deep learning system (DLS) that uses color fundus photographs
(CFPs) to predict the development of mild-or-worse (“Mild+”) DR within two years, for diabetic
patients without DR. The DLS was created using a large retrospective longitudinal dataset
collected in a DR screening program. Significant improvement in risk stratification was observed
on two independent datasets from different countries and ethnicities. The use of an automated
risk stratification tool could help scale DR screening as the number of patients with diabetes
continues to grow.
Implications of all the available evidence
Our risk stratification tool could be used by clinicians to optimize DR screening intervals.
Diabetic patients identified by our algorithm as high risk could be followed up more closely to
improve visual outcomes, while lower risk patients could be followed up less frequently to
reduce the burden of screening. More effective screening strategies are particularly important
given the recent challenges introduced by the COVID-19 pandemic. The risk prediction, in
concert with personalized patient education could motivate patients to undertake lifestyle
modifications or increase their adherence to therapy for improved blood sugar control. Finally,
our tool could aid further research into diabetes management and treatment. Prospective
studies are required to validate the DLS as a risk predictor for DR development and its
effectiveness in real world screening programs and clinical settings.
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Introduction
Diabetic retinopathy (DR) is the leading cause of irreversible blindness among adults aged
20-74 years globally.1 Because treatments are available to slow, halt, or effectively reverse
progression during the early stages of DR, regular screening is key to preventing blindness.
However, since the total number of diabetic patients is expected to increase from 415 million in
2015 to 642 million in 2040,2 the burden of screening and subsequent follow-up is a significant
challenge. The efficiency of DR screening programs may be improved using risk stratification
tools that can help personalize screening frequencies based on the likelihood of development or
progression of DR.3 In this work, we created a deep learning system (DLS) that uses color
fundus photographs (CFPs) to predict the risk of developing DR.
DR is a consequence of injury to the retinal microvasculature from diabetes. Most diabetic
patients develop DR during the first two decades of having diabetes.4 Without suitable
intervention, DR can develop and eventually progress from mild or moderate stages to
vision-threatening diabetic retinopathy (VTDR: severe nonproliferative DR, proliferative DR,
and/or diabetic macular edema).5 With the goal of early detection, DR screening is widely
recommended by major organizations such as the American Diabetes Association (ADA),6
International Council of Ophthalmology (ICO)7 and American Academy of Ophthalmology
(AAO).8 The recommended screening frequencies vary based on the local resource availability
and the stage of DR. For no or mild DR, the recommended frequency ranges from every 12 to
every 24 months.
Signs of retinal microvascular changes caused by diabetes are visible in CFPs, and thus they
are routinely used to assess the stage of DR. In addition to DR stage, the risk of development
and progression is influenced by systemic risk factors. Modifiable risk factors include
hyperglycemia, hypertension, dyslipidemia and obesity, smoking, anemia, pregnancy, low health
literacy, inadequate healthcare access, and poor adherence to therapy.9,10 Ethnicity, family
history or genetics, age at onset, type of diabetes, and duration of diabetes are non-modifiable
risk factors for the development and progression of DR.9
In this work, we focus on using CFPs, in addition to several known risk factors, to improve
stratification of risk of developing DR. Notably, this is a challenging task, since microvascular
changes are not known to be detectable in CFPs prior to development of DR. Consequently,
current CFP-based grading systems, such as the Early Treatment Diabetic Retinopathy Study
(ETDRS),11 International Clinical Diabetic Retinopathy (ICDR),12 and The Royal college of
Ophthalmologists Diabetic Retinopathy guidelines13 do not further risk stratify such cases.
However, since the majority of patients in a DR screening program show no signs of DR (>85%
in both datasets in our study), and typically only a small fraction of these patients require retinal
intervention within 2 years,14 risk stratification of this subgroup is an important problem. We
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hypothesized that for patients who show no signs of DR, a DLS using CFPs may be able to
provide such stratification.
Using a longitudinal dataset of CFPs, we created a DLS to predict whether eyes will develop
mild-or-worse (“Mild+”) DR within the following two years. In two validation datasets, we show
significant improvements in risk stratification both using CFPs alone, and when combined with
available risk factors as compared to using risk factors only. Additionally, we show that the
learned risk stratification generalizes across outcomes at different time points as well as when
evaluated against more severe stages of DR. We believe this system could aid in
clinical-decision making such as optimizing screening intervals, target lifestyle modifications or
counseling, and enable further research in diabetes management and treatment.
Methods
Datasets
We used de-identified CFPs from two datasets (Table 1). The first dataset comprised 362,283
patients with a total of 430,917 retinal examination visits from EyePACS LLC, a teleretinal DR
screening service in the U.S.. The standard imaging protocol was to capture three 45° fields of
CFPs (nasal, primary, and temporal) per eye. Different devices were used at the screening sites
including Canon (CR1 and CR2), Topcon (NW200 and NW400), Zeiss Visucam, Optovue iCam,
and Centervue DRS. Visits lacking any of the three fields were excluded. The average follow-up
amongst patients with two or more visits was 26.7 months (median: 21.4, interquartile range:
13.8-33.9, range: 0-126). The EyePACS dataset was randomly split into development and our
first validation set (validation set A) in an 8:2 ratio while ensuring no patients overlapped. The
development set was used to train and tune a DLS to predict the development of DR amongst
eyes without DR at their first visit (see details in “Algorithm development”). The DLS was then
validated on validation set A, which contained 7,976 eyes after selecting a random eye per
patient and restricting to eyes with more than two visits where the first visit had no DR. The
histogram of inter-visit time is plotted in Supplementary Figure S1A and the HbA1c distribution is
visualized in Supplementary Figure S2.
The second dataset was from Thailand and contained 6,791 patients.15 Patients were randomly
identified from the Thai national diabetic patients registry, representing hospitals or health
centers in each of the 13 health regions in Thailand. The standard imaging protocol involved
taking 45° primary field CFPs. The dataset contained images captured using various devices:
Topcon TRC-NW8, Nidek (AFC-210 and AFC-230), KOWA (Nonmyd α-DIII 8300, Nonmyd 7,
VX-10α, Nonmyd α-DIII, Nonmyd WX, VX-20). The histogram of inter-visit time is plotted in
Supplementary Figure S1B. Most patients were followed up after approximately 2 years
(average: 21.4 months, median: 23, interquartile range: 19-24, range: 2-35). One random eye
per patient was selected, and both visits for those eyes were graded (see details in “Grading
procedure”). When considering only those with two gradable visits and no DR at the first visit,
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4,762 eyes remained. This dataset was used as a second, external validation set (validation set
B). The HbA1c distribution for this dataset is visualized in Supplementary Figure S2.
All images and metadata were de-identified according to the Health Insurance Portability and
Accountability Act (HIPAA) Safe Harbor provision before transfer to the study investigators.
Ethics review and institutional review board exemption was obtained from Advarra Institutional
Review Board.
Endpoint definition
This work dealt with predicting development of DR, defined as whether an eye without DR at the
initial visit was graded as having Mild+ DR within 2 years. Because DR can develop in between
two visits, a Mild+ grade given during a visit implies that the disease progression happened
between the prior and the current visit. To account for this and real-world scheduling logistics for
in-person DR screening visits, we used a “buffer” of 1 month (28 days) for this binary endpoint
definition. Specifically, we considered an eye as positive for our endpoint if a visit corresponding
to Mild+ DR happened within 2 years after the initial visit or during the month following the
2-year mark. For eyes that did not meet this criterion, we required that the eye had a no-DR visit
after 2 years, or during the month prior to the 2-year mark to be considered negative. Eyes that
did not satisfy either of these criteria were excluded for evaluations involving this binary
endpoint. However, eyes without a known 2-year Mild+ DR endpoint were considered for the
survival analysis (see “Algorithm evaluation” below).
Grading procedure
Images from EyePACS (development set and validation set A) were graded for DR lesions by
EyePACS-certified graders based on a modified ETDRS grading protocol.16 Graders graded
each eye based on all three fields (nasal, primary, and temporal). The absence, or presence and
severity of individual lesions were mapped to 5 DR levels (no DR, mild, moderate, severe, and
proliferative DR) and diabetic macular edema (DME) (Supplementary Table S1). Each image
from the Thailand dataset (validation set B) was graded by one retina specialist from a pool of
11 specialists (average years of experience: 4 years; range: 1-9) using a similar grading protocol
(Supplementary Table S2). Images that were considered ungradable were excluded from the
study.
Algorithm development
A DLS based on the Inception-v318,19 architecture was trained on the train set (⅞-th of the
development dataset) and tuned using the tuning set (⅛-th of the development set). Within the
training set, only 25,211 out of 503,527 eyes had known 2-year Mild+ DR outcomes (Table 1).
To make use of all of these data, we leveraged the fact that all eyes were labeled with the
presence or absence of lesions and corresponding DR grade using multi-task learning.
Specifically, we tasked the DLS with simultaneously learning to grade DR and DME, detect the
presence of individual lesions, and predict other outcomes such as moderate-or-worse DR and
VTDR at multiple future time points. More details and specific hyperparameters are reported in
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Supplementary Table S3. Alternative modeling approaches are described in Supplementary
Methods and Supplementary Table S4.
We developed two versions of the DLS, one that takes as input the primary field (indicated as
“1-field”), and another that takes three fields as input (nasal, primary, and temporal; indicated as
“3-field”). We present the results for both versions of the DLS for the EyePACS validation set
(that contains all 3 fields). However, because the Thailand dataset contained only the primary
field, we evaluated only the 1-field version on this dataset. Both versions of the DLS take as
input CFPs of size 587x587 pixels and output a number between 0 and 1 representing the
likelihood of an eye developing DR within 2 years.
Rescaling of predicted likelihoods was found (post-hoc) to be necessary to calibrate predicted
probabilities in the external validation set B. Specifically, we applied the DLS to 5% of the eyes
in validation set B, and empirically determined a constant factor for linearly rescaling the
predicted likelihood (between 0 and 1) such that the average rescaled likelihood matched the
incidence of DR within 2 years. This resulting scaling factor (0.65) was then used on the full
validation set B to produce calibration plots.
Algorithm evaluation
We evaluated the DLS’s ability to predict development of DR in multiple ways. First, we
evaluated the discriminatory performance using the area under the receiver operating
characteristic (area under ROC; AUC). Next, we evaluated the calibration of the model by
plotting the observed event rate against the predicted event rate, based on deciles of risk
predicted by the DLS. Additionally, we evaluated the positive and negative predictive values for
the DLS predictions at all percentiles of DLS prediction.
To further evaluate the DLS with respect to outcomes that occurred beyond 2 years, we
conducted survival analysis with Kaplan-Meier curves, log-rank tests, and Cox proportional
hazards regression models. For the Kaplan-Meier curves and log-rank tests, thresholds for
high-risk and low-risk were based on the upper and lower quartiles of DLS prediction in the
tuning set.
Comparison and integration with risk factors
Finally, to compare prognostication by the DLS to that by risk factors at the time of the first visit,
we trained univariable and multivariable logistic regression models on the development set, and
evaluated them on the validation sets. Different risk factors were available in each dataset, and
each experiment included only the patients who had those risk factor(s) available. For
EyePACS, HbA1c, self-reported diabetic control, years with diabetes, and insulin use were
available. Diabetic control was reported as poor, fair, moderate, good, or excellent. Insulin use
was defined as either patient self-reported, or when present in the electronic medical record. For
the Thailand dataset, HbA1c and hypertension status were available. Categorical variables were
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encoded as dummy variables. The risk factors were also processed to handle extreme outlier
values (Supplementary Methods).
Statistical analysis
Survival analysis was conducted in Python using the lifelines library v0.24.6. Confidence
intervals for proportions (sensitivity, specificity, positive/negative predictive values) were
calculated using the Clopper-Pearson method based on the Beta distribution (as implemented in
Python's statsmodels library, v0.10.1), for the AUC using the DeLong method, and for the
Kaplan-Meier plots using the Greenwood Exponential formula. Statistical significance was
evaluated using the likelihood ratio test for the Cox models, and the logrank test for the
Kaplan-Meier analysis.
Model Explanation
To understand how the DLS was able to predict the development of DR from CFPs, we used
two strategies. First, we used several saliency techniques (Integrated Gradients, Guided
Backprop and Blur Integrated Gradients)20–22 that highlight the pixels with the greatest impact on
the DLS’s prediction for each individual image. For example, this enables us to identify areas of
the CFP the DLS might have been using to make a prediction for each case that progressed,
but for which there were no signs of DR. The second strategy we adopted was an “input
ablation” approach: systematically including or excluding certain fields or regions of each image
by replacing them with a mask during training as well in evaluation. For the region-based
analysis, the outer rim and top and bottom parts of the image were cropped slightly to ensure
consistent contours between images from different devices, and the processed image was split
into 5 regions with equal area (Figure 5C). The consequent drop in performance allows us to
identify retinal areas that are most important in prognostication generally across the whole
dataset.
Results
In this study we used two datasets; the DLS was developed using a subset of the EyePACS
dataset (train set, n=503,527 eyes; tune set, n=71,904 eyes), and evaluated on an independent
subset of EyePACS (validation set A, n=7,976 eyes) and the Thailand dataset (validation set B,
n=4,762 eyes). The baseline characteristics, demographics and distribution of the DR grades
from the datasets used are shown in Table 1. Amongst eyes with known 2-year Mild+ DR
outcomes in the two validation datasets (n=3,678 and 2,345, respectively), 15-19% of the eyes
without DR developed some level of DR within 2 years.
The 3-field DLS’s AUC for predicting development of DR in validation set A was 0.79 (95%CI:
0.77-0.81). The 1-field DLS’s AUC was 0.78 (95%CI: 0.76-0.80) in validation set A and 0.70
(95%CI: 0.67-0.74) in validation set B. These results are illustrated in Supplementary Figure
S3A-C, while corresponding results for a subset of both validation sets that had available risk
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factors were nearly identical and presented in Figure 1A-C. The comparison with risk factors will
be detailed in a subsequent section. Both versions of the DLS were well-calibrated for validation
set A (Figures 1D-E). In validation set B, however, consistent with a substantially lower
incidence of DR (15% vs 19%), the 1-field DLS over-estimated the rate of developing DR. This
overestimation was resolved after a simple scaling using 5% of validation set B (Figure 1F). This
calibration does not affect the AUC analysis.
Positive predictive values (PPV) and negative predictive values (NPV) as a function of the risk
threshold are illustrated in Figure 2. Because the incidence rates were below 20%, the NPVs
were generally higher than 80%, exceeding 95% for the lowest-risk group. The PPVs increased
sharply in the high-risk group, with the predicted risk of developing DR in the highest-risk decile
of patients ranging from 40% to 60%.
Results from univariable analyses comparing the DLS to known risk factors, and multivariable
analysis evaluating if the DLS could improve prognostication when added to risk factors are
presented in Table 2A and Figure 1A-B for validation set A. The most predictive risk factor in
univariable analysis was HbA1c (AUC of 0.68). The remaining risk factors had AUCs ranging
from 0.59 to 0.64. The combination of all risk factors using multivariable logistic regression
achieved an AUC of 0.72. Upon adding the prediction of the 3-field DLS as another variable to
the logistic regression model, the AUC increased from 0.72 to 0.81. The effect of instead adding
the prediction of the 1-field DLS was similar albeit with slightly smaller improvements, with the
AUC increasing to 0.79. In the same cohorts, the DLS alone achieved consistent AUCs of about
0.79 using 3-fields and 0.77-0.78 using 1-field. The results of several weakly-prognostic risk
factors are reported in Supplementary Table S5. In validation set B, the only overlapping risk
factor with the development sets was HbA1c. Thus, we next compared HbA1c alone to a model
that also includes the DLS (i.e., the model from the first row of Table 2A). The addition of the
DLS improved the AUC from 0.62 to 0.71 in validation set B (Table 2B and Figure 1C). In
contrast to adding the DLS to risk factors, the difference between using the DLS in isolation and
adding risk factors to the DLS was much more modest at 0.01-0.02 absolute improvement in
both validation sets.
Next, we used Kaplan-Meier analysis to examine the association of the DLS with development
of DR over time. First, we defined high-risk, medium-risk, and low-risk groups using the
thresholds for upper and lower quartiles of DLS prediction in the tuning dataset. Kaplan-Meier
plots illustrating rates of development of DR are presented in Figure 3A for the 3-field DLS on
validation set A, and Figures 3B-C for the 1-field DLS on the two validation sets. A clean
separation between the low and high risk groups’ rates of development of DR was observed in
these evaluations (p<0.001). Corresponding analyses for how the same risk groups progressed
to moderate-or-worse DR and VTDR are presented in Figures 3D-I. We observed that the risk
groups remained separated even when progression to more advanced stages of DR are
considered (p<0.001).
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Cox regression analysis is presented in Supplementary Tables S6A-B. The DLS predictions
were significantly associated (p<0.001) with development of DR both in univariable analysis and
after adjusting for HbA1c, self-reported diabetic control, years with diabetes, and insulin use in
validation set A. Similar results were observed in validation set B, with multivariable adjustment
for HbA1c and self-reported hypertension.
Next, we evaluated if there was a temporal relationship between the predicted risk of developing
DR and the time-to-DR (Supplementary Figure S4). At 4-8 years before DR developed, the
baseline median predicted DR risk remained constant at approximately 10%. The median
predicted risk increased to approximately 20% 3 years prior to DR, to approximately 25% 2
years before DR, and to approximately 40% 1 year before DR developed.
To better understand the CFP features that our system had identified as being prognostic for
developing DR, we employed three explanation techniques: Integrated Gradients, Guided
Backprop, and BlurIG.20–22 We present results for four cases using the Integrated Gradients
method in Figure 4 and defer the full set of results to Supplementary Figure S5. For cases
without signs of DR at baseline but that later developed DR, we observed both cases where the
heatmaps highlighted areas which eventually developed lesions (Figure 4A-B), and cases
where the heatmap highlights did not show lesions at the follow-up visit (Figure 4C). For the
case in Figure 4D that already had subtle microaneurysms, the heatmaps highlighted the
existing lesions. Figure 4E shows a case that did not develop DR in 6 years of followup.
Finally, we present results from input ablation experiments (Methods). For the first set of
experiments, we considered the 3-field DLS, and ablated either one or two fields of input (Figure
5A-B). Among single-field setups (ie, when removing two fields), the highest AUC was achieved
when retaining the primary field. Among the two-field setups (i.e., when removing one field), the
highest AUC was achieved when the fields covered the widest field of view (nasal and
temporal). In a second set of experiments, we considered the 1-field DLS and split the primary
field into 5 regions (see Methods) for inclusion or exclusion (Figure 5C-D). The central region
alone resulted in the highest AUC, while the inferior region alone resulted in the lowest AUC.
Discussion
In this study we created a DLS to predict development of DR within 2 years, and validated it on
two datasets. The first, internal validation set contained images from predominantly (59%)
Hispanic patients, while the second, external validation set were from Thai patients. On both
datasets, the DLS demonstrated good performance both in isolation, and when adjusted for
available risk factors. When combined with several risk factors including HbA1c, the
performance improved from using the risk factors alone. The Kaplan-Meier analysis added
further supportive evidence that the prognostication generalized to different time points and that
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the model’s predictions were also associated with progression beyond mild DR; to moderate DR
and VTDR as well.
The model was well calibrated for validation set A, but overestimated DR incidence in validation
set B. This overestimation may be associated with the lower incidence rate in validation dataset
B (15% vs 19%), which is in turn consistent with a lower proportion of patients with high HbA1c
(Supplementary Figure S2). Differences in grading protocols (Supplementary Table S1 & S2)
may also have contributed to this. Specifically, the presence of hemorrhages or hard exudates
without microaneurysms were considered moderate DR in validation set A, but no DR in
validation set B. This affects our inclusion criteria and the endpoint. Moreover, validation set A
was labeled by trained graders, whereas validation set B was labeled by retina specialists for
the purposes of this study. The calibration difference was resolved when 5% of validation set B
was used to recalibrate the model. In real use cases, retrospective data may suffice for
recalibration, though this will need to be studied in future work.
In recent years, deep learning applied to CFPs or OCTs has shown great promise for many
diagnostic tasks.23–25 In ophthalmology, deep learning has been used to automatically detect or
grade DR.26–31 The first approval from the U.S. Food and Drug Administration (FDA) for an
autonomous artificial intelligence system for DR detection was granted in 2018.32 Going a step
further, this approach has tackled tasks not known to be possible even for human experts,
suggesting that deep learning models can potentially detect novel signs of disease. For
instance, models using CFPs have been shown capable of detecting anemia,33 predicting
cardiovascular risk factors,34 and determining DME and glaucoma-related damage that
otherwise needed optical coherence tomography (OCT) or additional tests for a diagnosis,17,35,36
predict the progression of DR,37 progression of age-related macular degeneration,38–40 and
development of glaucoma.41
There are also several examples of algorithms for stratifying risk of DR. Estil et al. used an
algorithm to reduce the frequency of screening visits based on individual risk factors for DR
progression.42 Cunha-Vaz et al.,43 found that in eyes with mild non-proliferative DR, increased
microaneurysm turnover rate and central macular thickness were correlated with an increased
risk of progression to DME.43 Using deep learning, Arcadu et al. 37 predicted DR progression,
defined as worsening of 2 or more steps on the ETDRS scale at 6, 12 and 24 months, with
AUCs of 0.68, 0.79 and 0.77, respectively. The limitations of the study were lack of adjusted
analysis for risk factors, lack of external validation set, limited study size (n≈530) and the
consequent use of cross-validation, and a restrictive inclusion criteria (patients from two clinical
trials). A multivariable model developed using multifocal electroretinogram achieved 86%
sensitivity and 84% specificity for predicting new retinopathy development at specific locations
in the retina over one and two years.44 A study by Rogers et al.,45 found that retinal arteriolar
dilation increased the risk of incident DR over 5 years in an Australian cohort suggesting retinal
arteriolar dilatation could be a preclinical biomarker for DR.
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Our study improves upon prior work in several ways. Firstly, we consider the challenging task of
stratifying patients by their risk of developing DR using CFPs and risk factors, which are
available in most screening settings. This directly tackles the problem of optimizing screening
intervals by stratifying the largest group in screening: those without any DR. Second, our system
retained high prognostic value after adjusting for several risk factors which suggests the
development of independent imaging-based biomarkers is a fertile area of further research.
Thirdly, we validated our system on two separate validation datasets from two continents. Both
datasets represented their region’s diabetic screening patient population; and our system
retained substantial predictive value despite differences in HbA1c levels (Supplementary Figure
S2), average incidence rates (Table 1), and grading protocols (Supplementary Tables S1 and
S2). In addition, our development sets spanning multiple years of follow-up are orders of
magnitude larger than prior work. Finally, the risk groups constructed based on our system
retain significant separation even when evaluated against different endpoints
(moderate-or-worse and VTDR plots in Figure 3D-I).
Moreover, we conducted several analyses to better understand the features in the CFPs that
are predictive of future development of DR. First, our model predicts a very high likelihood of
developing DR when there already exists subtle microaneurysms that were missed by the initial
grader. While this signifies cases that were meant to be excluded from the study, subtle
microaneurysms can be missed in real settings. As such, it is comforting that such cases are
flagged with high certainty by the DLS, which could prompt graders to take a more careful look
at the eye. Second, the saliency (heatmap) analysis in Figure 4 and Supplementary Figure S5
suggests that the DLS sometimes “focuses on” anatomic regions that eventually develop DR.
This suggests that there may be subtle signs that are not visually apparent, and this
phenomenon merits study in future work. Third, in terms of the field, the primary field was found
to be most important. At the same time, the best combination of two fields was the nasal and
temporal (excluding the primary field). These observations can be reconciled by considering that
(1) the combination of the nasal and temporal fields encompasses the primary field, and (2)
these two fields when combined provide the most expansive view of the retina. Finally, within
the primary field, we observed that the superior and inferior regions seemed to be the least
important by virtue of having the least impact when excluded. Conversely, the macular region
had the greatest impact when removed and was also the most prognostic in isolation. Thus it
seems important for the DLS to have both information about the macula specifically, and
information from the periphery of the retina to predict the development of DR.
In terms of utility, one application of the ability to predict the development of DR can be in
optimizing screening intervals. The availability of effective treatments such as laser
photocoagulation and intravitreal injections of anti-vascular endothelial growth factor46–48 have
elevated the importance of early detection via screening. Traditionally, DR screening was
performed by a clinician using direct or indirect ophthalmoscopy or slit lamp biomicroscopy.
However, fundus photography and its review by a remote clinician is becoming more
widespread because of its cost-effectiveness and acceptable sensitivity and specificity rates.49
Multiple DR screening guidelines recommend screening intervals based on assessment of
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CFPs.7,8,50 However, these guidelines provide a range of values for the screening interval (e.g.
12-24 months for patients with no apparent DR) to account for clinical risk factors, resource
availability, and other socioeconomic factors. Our tool can provide a more accurate personalized
risk assessment to help determine optimal screening intervals; high-risk patients can be
followed frequently to ensure early detection, while low-risk patients could be followed less
frequently to reduce screening burden shared by patients, clinicians, and the healthcare system.
Such strategies based on the risk assessments, and corresponding interventions will need to be
studied in future work.
Other potential use cases of predicting the development of DR revolve around targeted
interventions. For example, high-risk patients could be preferentially selected for more intensive
lifestyle modifications or counseling.51,52 These patients may also be better suited for stricter
pharmacologic control of blood sugar, and could be suitable candidates for participation in
relevant clinical trials. Patients sometimes miss their screening visits, and in such cases, our
tool can be used to alert high-risk patients (e.g. via phone calls or emails) to improve screening
compliance and consequently visual outcomes. Finally, the ability of the DLS to predict the
development of DR that occurs beyonds 2 years (Figure 3) suggests the tool may also be useful
in long-term forecasting of population-level DR prevalence for public health planning.
Limitations
Our study has several limitations. First, several known risk factors such as blood pressure were
not available for both datasets, and so we could not compare the DLS to these risk factors, or
adjust for them in multivariable analysis. Some risk factors such as HbA1c were also potentially
from an earlier blood test, which adds uncertainty to the HbA1c at the time of DR screening.
Second, as demonstrated in Figure 4, grading variability exists, especially for subtle findings
such as microaneurysms. As such, a subset of our cohort already had mild DR at baseline.
Though it is semantically correct that our model predicted these images as “will develop DR”
with high certainty, users of a tool such as this should be aware that eyes with unreasonably
high predicted risk may have already developed DR. Potential solutions to this include the use
of automated DR grading algorithms in parallel with a risk stratification tool, and could be
investigated in future work. Next, since our grades were based on 3 fields for validation set A
and a single field for validation set B, lesions outside of the fields may remain undetected.
Finally, since the data came from screening programs, patients in both datasets were generally
referred when moderate-or-worse DR was discovered, and the lack of OCT limited the accuracy
of detecting DME. Thus, neither dataset was ideal for evaluation of progression to VTDR.
Conclusions
Our results suggest that a DLS can be developed to stratify patients by their risk of developing
DR. Further studies could help understand the effectiveness of interventions tailored to
progression risk (e.g. screening intervals) towards improving health outcomes and reducing
cost.
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Tables
Table 1. Baseline characteristics.
Characteristics
Development Dataset Validation Datasets
Training Dataset
(EyePACS)
Tuning Dataset
(EyePACS)
Validation
Dataset A
(EyePACS)
Validation
Dataset B
(Thailand)
No. of patients 253,598 36,228 72,457 6,791
No. of eyes 503,527 71,904 143,864 13,573
No. of eyes with at least one set of images with available
grades
365,144 52,456
104,695
6,307
No. of eyes selected (random eye per patient in validation
sets; see Methods) 52,403
No. of eyes with at least two sets of gradable images (on
different visits) 63,281 9,333 9,124 5,603
No. of eyes with at least two sets of gradable images and
without DR at the first visit (No. of patients) 55,561 (31,449) 8,211 (4,651) 7,976 (7,976) 4,762 (4,762)
Age (years), median (IQR) 53 (46-60) 54 (45-60) 54 (45-60) 59 (52-66)
No. of females / total* (%)
19,919 / 31,447
(63.3%)
2,905 / 4,649
(62.5%)
5,118 / 7,975
(64.2%)
3,277 / 4,759
(68.9%)
Race / Ethnicity (%)
Hispanic: 59.0%
White: 7.3%
Asian / Pacific
Islander: 5.3%
Black: 4.0%
Native American:
1.3%
Other: 1.5%
Not available:
21.5%
Hispanic: 58.3%
White: 7.4%
Asian / Pacific
Islander: 4.9%
Black: 3.8%
Native American:
1.2%
Other: 1.6%
Not available:
22.7%
Hispanic: 58.7%
White: 7.6%
Asian / Pacific
Islander: 4.8%
Black: 4.6%
Native American:
1.2%
Other: 1.7%
Not available:
21.5%
Thai: 100%
HbA1c (%), median, (IQR) 6.5 (7.3-8.9) 6.5 (7.2-8.9) 6.5 (7.3-9.0) 6.4 (7.2-8.4)
Outcome: mild-or-worse
(“Mild+”) DR within 2 years
Total no. of eyes with known
outcome** 25,211 3,688 3,678 2,345
No. of eyes with Mild+
outcome (%) 4,529 (18.0%) 635 (17.2%) 685 (18.6%) 346 (14.8%)
Outcome:
moderate-or-worse
(“Moderate+”) DR within 2
years
Total no. of eyes with known
outcome** 24,393 3,609 3,554 2,292
No. of eyes with Moderate+
outcome (%) 2,093 (8.6%) 303 (8.4%) 317 (8.9%) 225 (9.8%)
Outcome:
vision-threatening DR
(VTDR)*** within 2 years
Total no. of eyes with known
outcome** 24,104 3,602 3,500 2,219
No. of eyes with VTDR
outcome (%) 256 (1.1%)
37 (1.0%) 43 (1.2%) 69 (3.1%)
Abbreviations: DR, Diabetic Retinopathy; IQR, Interquartile Range; HbA1c, Glycated hemoglobin. *A small number of patients did
not have this information available. **See “Methods” for binary endpoint definition. ***includes diabetic macular edema.
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Table 2. Predictive performance by the deep learning system (DLS) applied to color fundus
photographs (CFPs), in comparison to and in combination with known risk factors for (A) the
EyePACS validation dataset and (B) the Thailand dataset. The highest value(s) in each row are
highlighted. A more comprehensive set of risk factors are reported in Supplementary Table S5. *The only
risk factor in validation set B that was also available and prognostic in the development set was HbA1c.
A
Risk factor(s) No. of
eyes with
risk
factor(s)
available
No. of eyes
that
developed
DR within 2
years
AUC [95%CI]
Risk factor(s)
alone
Using 1-field CFP Using 3-field CFPs
DLS alone Risk factor(s)
+ DLS
DLS alone Risk factor(s) +
DLS
HbA1c 2,534 458 (18%) 0.68
[0.65, 0.71]
0.78
[0.75, 0.80]
0.79
[0.77, 0.82]
0.79
[0.76, 0.81]
0.81
[0.78, 0.83]
Years with
diabetes
3,223 615 (19%) 0.64
[0.61, 0.66]
0.77
[0.75, 0.79]
0.78
[0.76, 0.80]
0.79
[0.76, 0.81]
0.80
[0.77, 0.82]
Self-reported
diabetic control
1,589 274 (17%) 0.64
[0.61, 0.68]
0.77
[0.73, 0.80]
0.78
[0.75, 0.81]
0.79
[0.76, 0.82]
0.80
[0.77, 0.84]
Insulin use 3,678 685 (19%) 0.59
[0.58, 0.61]
0.78
[0.76, 0.80]
0.78
[0.76, 0.80]
0.79
[0.77, 0.81]
0.80
[0.78, 0.82]
HbA1c,
years with
diabetes,
self-reported
diabetic
control,
insulin use
1,257 221 (18%) 0.72
[0.68, 0.76]
0.77
[0.73, 0.81]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
0.81
[0.77, 0.84]
B
Risk factor(s)* No. of
eyes with
risk
factor(s)
available
No. of eyes
that
developed
DR within 2
years
AUC (95%CI)
Risk factor(s)
alone
Using 1-field CFP
DLS alone Risk factor(s)
+ DLS
HbA1c 1,788 268 (15%) 0.62
[0.58, 0.66]
0.70
[0.67, 0.74]
0.71
[0.68, 0.75]
Abbreviations: DR, Diabetic Retinopathy; AUC, Area Under the Curve; CFP, Color Fundus Photograph;
DLS, Deep Learning System; HbA1c, Glycated hemoglobin.
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Figures
3-field DLS (validation set A) 1-field DLS (validation set A) 1-field DLS (validation set B)
A B C
D E F
Figure 1. Discrimination and calibration of the deep learning model for predicting incidence of
diabetic retinopathy (DR). (A,B) Receiver operating characteristic (ROC) curves for 3-field and
1-field DLS for validation set A. Curves are shown for risk factors in Table 2, for the DLS alone,
and for the combination of these risk factors (RFs) and the DLS. To enable comparison, ROCs
were plotted only for patients with known values for the RFs; the ROC for the DLS on the entire
validation set is presented in Supplementary Figure S3A-C. (C) ROC curve for the 1-field DLS
for validation set B. (D,E,F) Calibration plots corresponding to the models in panels A-C, for the
entire validation datasets. Each plot compares actual vs. average predicted risk, with each blue
dot representing a decile of predicted risk. Because the DLS was less well calibrated on
validation set B, the DLS was recalibrated and visualized in panel F as orange dots.
21
A 3-field DLS (validation set A) B 1-field DLS (validation set A) C 1-field DLS (validation set B)
Figure 2. Positive predictive value (PPV, blue line) and negative predictive value (NPV, orange
line) of the deep learning system (DLS) for predicting development of diabetic retinopathy in
(A,B) validation set A using 3-field and 1-field models respectively. (C) Analysis for validation set
B using the 1-field model. The shaded regions indicate 95% confidence intervals.
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3-field DLS (validation set A) 1-field DLS (validation set A) 1-field DLS (validation set B)
A B C
D E F
G H I
Figure 3. Kaplan Meier plot illustrating the incidence of diabetic retinopathy (DR). The red,
black, and green lines represent high risk, moderate risk, and low risk as stratified by the deep
learning system using the upper and lower quartiles in the tuning dataset. (A,B) Plots for 3-field
and 1-field DLS for validation set A. (C) Plot for 1-field DLS for validation set B. Note that
validation sets A and B have different follow-up durations. (D-F) represent the same risk groups
in panels A-C progressing to moderate-or-worse DR; (G-I) represent the same risk groups in
panels A-C progressing to vision-threatening DR (VTDR).
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Figure 4. Example cases with a color fundus photograph (CFP) at baseline (leftmost column), saliency heatmaps
(middle column) using Integrated Gradients22 explanation technique on the CFP from the baseline visit, and a
follow-up visit (rightmost column). In each saliency map, the color represents the strength of the contribution towards
the prediction; red indicates a contribution towards developing DR, yellow indicates contribution towards not
developing DR, whereas blue indicates little contribution. (A) This case did not have diabetic retinopathy (DR) at
baseline visit (age=43 years), but developed DR on a future follow-up visit (age=44 years). The prediction was high
(0.75) and the highlighted regions in the saliency map eventually developed microaneurysms. Note that not all future
microaneurysms were highlighted. (B) This case also did not have diabetic retinopathy (DR) at baseline visit (age=48
years), but developed DR on a future follow-up visit (age=50 years). The prediction was high (0.71) and the
highlighted regions in the saliency map eventually developed microaneurysms. (C) This case did not have DR at the
baseline visit (age=34 years), but developed DR at the followup visit (age 37 years). The prediction was high (0.68),
but the highlighted regions did not show microaneurysms at the follow-up visit. (D) This case had a very high DLS
prediction (0.97), and upon closer inspection the baseline image showed subtle signs of mild DR, as evidenced by
microaneurysms. The saliency map correctly highlighted the microaneurysms at baseline. (E) This case did not have
DR at the baseline visit (age=64 years) and also did not develop DR at the latest available follow-up visit (age=70
years). The DLS correctly assigned a small probability of progression (0.06).
24
Figure 5. Importance of different fields and different parts of the image. A. Sample images of
each of the three fields. B. Deep learning system (DLS) performance using one or two images
from three-field images compared to the performance using all three images (vertical black
lines). The thick vertical black line indicates the mean, and the thin vertical black lines indicate
the standard deviation across three training runs. C. The left column contains sample images of
the primary field with several different regions indicated by letters: S: Superior, T: Temporal, C:
Central, N: Nasal, and I: Inferior. The middle column contains sample images with only one of
the regions (Nasal in this example). The right column contains sample images that exclude one
region (Nasal in this example). D. DLS performance after systematically including only each
region or excluding that region, compared to the performance using all the regions (vertical
black lines). The thick vertical black line indicates the mean, and the thin vertical black lines
indicate the standard deviation across three training runs. Error bars (horizontal black lines)
similarly indicate one standard deviation across three training runs.
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Supplement
Supplementary Methods
Visualization of differences between patients with vs those without followup
To better understand if there were differences between the patients who had follow-up visits in
our dataset vs those who did not, we visualized the differences in several baseline variables as
well as the DLS prediction (Supplementary Table S7).
Handling outlier values for risk factors
To ensure the logistic regression models were not inordinately influenced by outliers in the risk
factors (e.g. caused by errors in data entry), some processing was performed on the data. For
age, values less than 1 or higher than 122 were removed, whereas values between 90 and 122
were set to 90. HbA1c less than 1% and greater than 18% were removed. “Years with diabetes”
values were clipped to be between 1 and 20.
Comparison of different modeling approaches
In addition to the methods described in the main text, we explored several other neural network
modeling approaches and selected the best method based on the results on the tune set
(Supplementary Table S4). First, we trained a network to grade for DR on the five-point scale
(Supplementary Table S1). The five-point prediction of this network resulted in an AUC of 0.58.
However, applying logistic regression to the continuous predicted distribution over the five-point
scale resulted in a substantially higher AUC of 0.74. Next, we trained a network to grade for the
individual lesions listed in Supplementary Table S1. Applying logistic regression to the binary
predicted lesions resulted in an AUC of 0.57. Similarly, applying logistic regression to the
continuous predicted distribution of the lesions resulted in a substantially higher AUC of 0.76.
Finally, the methods described in the main text, which involves directly training a model to
predict development of DR while simultaneously “co-training” on current DR/DME grades,
lesions, and various future outcomes (Supplementary Table S4) resulted in the highest AUC of
0.80. When evaluating the combined models containing both the risk factors and 3-field CFPs,
the trends were identical, with a 0.04-0.17 increase in AUC compared to using CFPs alone.
We further explored how much training data was necessary for the performance observed
(Supplementary Figure S6). Our results suggest that the performance of the DLS had not
plateaued and could potentially increase further with more training data.
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Using a reference standard based on automated grading
As noted in the main text, some grading errors are inevitable for subtle findings such as
microaneurysms. To further validate our DLS, we used an alternative reference standard based
on automated grading. Specifically, a deep learning model was trained and tuned using the
development sets (see “Methods”) to classify the current stage of DR using 3-fields of CFPs. On
the tune set, this model had an AUC of 0.954 for classifying no DR vs Mild+ DR. This model
was applied to each set of CFPs in validation set A (See “Methods”) to obtain a probability
distribution over the five grades and the grade with the maximum probability was treated as the
automated DR grade. Next, using the automated grade as the reference standard, the DR
status at the first visit was evaluated to decide cohort inclusion for each eye; eyes with no DR at
the first visit were included. For each included eye, the reference standard for progression
endpoint was then computed (see “Endpoint Definition”) using the sequence of automated
grades at subsequent visits. We evaluated the 3-field DLS as described in the main text on this
new cohort with the new reference standard. The DLS had an AUC of 0.80 (95% CI: 0.77, 0.83).
This result further validates the performance of our DLS and provides evidence that the learned
risk stratification retains prognostic value against an endpoint defined via an accurate deep
learning model for classifying current DR grade.
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Supplementary Tables
Supplementary Table S1. Mapping of the graded lesions to corresponding DR levels and DME
for the EyePACS dataset. Lesions were graded by EyePACS following the ETDRS protocol, and
the mapping was customized to be as consistent as possible with mapping used for our graders
(Supplementary Table S2).
Lesions Grades
No lesions No DR
Microaneurysms only Mild
Hemorrhages with or without microaneurysms (HMA) <
2A
Moderate
Intraretinal microvascular abnormalities < 8A
Hard exudates
Cotton wool spots*
Focal laser scars
HMA > 2A Severe
Venous beading
Intraretinal microvascular abnormalities ≥ 8A
Neovascularization at disc or elsewhere Proliferative DR
Fibrovascular proliferation
Preretinal hemorrhage
Vitreous hemorrhage
Panretinal photocoagulation scars
Hard exudates* within 2 disc diameter DME
Abbreviations: DR, Diabetic Retinopathy; DME, Diabetic Macular Edema;
* Requires the presence of microaneurysms
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Supplementary Table S2. Definitions of DR levels and DME for the Thailand dataset based on
lesions present. The grades were directly provided by retina specialists (Methods).
Lesions Grades
No lesions No DR
Microaneurysms only Mild
Hemorrhages* Moderate
Hard exudates*
Cotton wool spots*
Focal laser scars
Greater density/count of hemorrhages Severe
Definite venous beading
Prominent IRMAs
Neovascularization at disc or elsewhere Proliferative DR
Fibrovascular proliferation
Preretinal hemorrhage
Vitreous hemorrhage
Panretinal photocoagulation scars
Hard exudates* within 2 disc diameter DME
Abbreviations: DR, Diabetic Retinopathy; IRMA, IntraRetinal Microvascular Abnormality;
* Requires the presence of microaneurysms
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Supplementary Table S3. Model hyperparameters
Hyperparameter Value or Setting
Preprocessing Fitting a circle, cropping, and resizing the image (see “resolution” below)
Image resolution 587 x 587 pixels
Data augmentation ● Vertical and horizontal reflections
● Brightness changes (max delta: 0.115 using
tf.image.random_brightness)
● Saturation changes (between 0.560 and 1.275, using
tf.image.random_saturation)
● Hue changes (between -0.025 and 0.025, using tf.image.random_hue)
● Contrast changes (between 0.9997 and 1.7705, using
tf.image.random_contrast)
Neural network backbone Inception-v318
Multi-image reduction Concatenation of feature maps
Dropout keep probability 0.8
Loss Cross entropy with weight decay = 4e-5
Co-training heads Current DR and DME grades, lesions, and future Mild+, Moderate+,
Severe+, VTDR, and PDR outcomes at 3, 6, 12 and 24 months
Network pre-initialization From ImageNet-pretrained checkpoint 53
Optimization algorithm and
settings
Adam54: batch size = 8, learning rate: 0.0003, β1 = 0.9, β2 = 0.999, ε = 0.1
Stopping criteria maximum number of training steps = 400,000 with early stopping based on
performance on tune set
Parameter averaging for
inference
Exponential decay with factor of 0.9999
Ensemble size for inference 10
Abbreviations: DR, Diabetic Retinopathy; DME, Diabetic Macular Edema; VTDR, Vision
Threatening Diabetic Retinopathy; PDR, Proliferative Diabetic Retinopathy.
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Supplementary Table S4. Comparison of different modeling approaches.
Modeling approach
AUC on tune set [95% CI]
3-field CFPs (N=3,688 eyes,
n=635 Mild+)
3-field CFPs and risk factors
(N=1,244 eyes, n=239 Mild+)
Using predicted 5-class DR
grade (one-hot encoded)
0.58 [0.57, 0.60] 0.75 [0.71, 0.79]
Using predicted distribution of
5-class DR grade (5 numbers
indicating likelihood of each
grade)
0.74 [0.72, 0.77] 0.81 [0.77, 0.84]
Using predicted lesions
(one-hot encoded)
0.57 [0.55, 0.58] 0.74 [0.70, 0.78]
Using predicted lesion
probability (one per lesion)
0.76 [0.74, 0.78] 0.81 [0.78, 0.84]
Using deep learning to
predict directly
0.80 [0.78, 0.82] 0.84 [0.81, 0.87]
Abbreviations: AUC, Area Under the Curve; CFP, Color Fundus Photograph; DR, Diabetic
Retinopathy;
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Supplementary Table S5. Predictive performance by the deep learning system (DLS) applied
to color fundus photographs (CFPs), in comparison to known risk factors for validation set A.
Race/ethnicity was also available and coded as Asian/Pacific islander, Black, Hispanic, Native
American, White, or Other.
1-field DLS 3-field DLS
Risk factor / Predictor N n RF-only Image-only RF+Image Image-only RF+Image
Hypertension (self reported) 927 210
(23%)
0.54
[0.50, 0.58]
0.79
[0.75, 0.83]
0.80
[0.76, 0.83]
0.80
[0.76, 0.84]
0.81
[0.78, 0.85]
Sex (self reported) 3677 685
(19%)
0.53
[0.51, 0.55]
0.78
[0.76, 0.80]
0.78
[0.76, 0.80]
0.79
[0.77, 0.81]
0.79
[0.77, 0.81]
Aspirin use 1528 271
(18%)
0.53
[0.50, 0.56]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.76, 0.82]
Sulfonylurea use 1528 271
(18%)
0.53
[0.50, 0.56]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.76, 0.82]
Ace inhibitor use 1528 271
(18%)
0.52
[0.49, 0.55]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Statin use 1528 271
(18%)
0.52
[0.49, 0.55]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Triglycerides level 1672 279
(17%)
0.52
[0.48, 0.56]
0.74
[0.70, 0.77]
0.74
[0.70, 0.77]
0.76
[0.72, 0.79]
0.76
[0.73, 0.79]
Beta blocker use 1528 271
(18%)
0.51
[0.50, 0.52]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Age 3678 685
(19%)
0.51
[0.49, 0.53]
0.78
[0.76, 0.80]
0.78
[0.76, 0.80]
0.79
[0.77, 0.81]
0.79
[0.77, 0.81]
Race / Ethnicity 2834 550
(19%)
0.51
[0.49, 0.53]
0.77
[0.75, 0.80]
0.78
[0.75, 0.80]
0.79
[0.77, 0.81]
0.79
[0.77, 0.81]
Total cholesterol level 1687 279
(17%)
0.51
[0.47, 0.55]
0.74
[0.71, 0.77]
0.74
[0.71, 0.78]
0.76
[0.73, 0.79]
0.76
[0.73, 0.79]
Alpha-glucosidase inhibitor use 1528 271
(18%)
0.50
[0.50, 0.50]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Angiotensin II receptor blocker use 1528 271
(18%)
0.50
[0.50, 0.50]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Prenatal vitamins use 1528 271
(18%)
0.50
[0.50, 0.50]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Dipeptidyl peptidase-4 inhibitor
use
1528 271
(18%)
0.50
[0.49, 0.51]
0.77
[0.74, 0.80]
0.77
[0.73, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Thiazolidinedione use 1528 271
(18%)
0.50
[0.48, 0.51]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.76, 0.82]
Biguanide use 1528 271
(18%)
0.48
[0.45, 0.50]
0.77
[0.74, 0.80]
0.77
[0.74, 0.80]
0.79
[0.75, 0.82]
0.79
[0.75, 0.82]
Abbreviations: DLS, Deep Learning System; RF, Risk Factor;
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Supplementary Table S6. Univariable and multivariable Cox analysis of the DLS in
comparisons with risk factors. (A) Analysis for validation dataset A; n=2,786 (the number of
eyes with all risk factors available). (B) Analysis for validation dataset B; n=3,404.
A
Risk factor(s) or
predictor
Univariable analysis Multivariable analysis
Hazard ratio [95%CI] p Hazard ratio [95%CI] p
DLS (per standard
deviation increase)
1.89 [1.83, 1.97] <0.001 1.80 [1.67, 1.94] <0.001
HbA1c (per % point
increase)
1.22 [1.19, 1.25] <0.001 1.15 [1.07, 1.22] <0.001
Self-reported diabetic
control: poor
Ref. N/A Ref. N/A
Self-reported diabetic
control: fair
0.65 [0.49, 0.86] 0.003 0.91 [0.64, 1.30] 0.612
Self-reported diabetic
control: moderate
0.62 [0.49, 0.79] <0.001 1.07 [0.77, 1.48] 0.707
Self-reported diabetic
control: good
0.35 [0.26, 0.46] <0.001 0.62 [0.40, 0.98] 0.039
Self-reported diabetic
control: excellent
0.26 [0.16, 0.41] <0.001 0.73 [0.41, 1.29] 0.277
Years with diabetes 1.08 [1.07, 1.10] <0.001 1.05 [1.02, 1.07] <0.001
Insulin use 2.39 [2.10, 2.73] <0.001 1.08 [0.83, 1.39] 0.561
Abbreviations: DLS, Deep Learning System;
B
Risk factor(s) or
predictor
Univariable analysis Multivariable analysis
Hazard ratio [95%CI] p Hazard ratio [95%CI] p
DLS (per standard
deviation increase)
1.75 [1.64, 1.87] <0.001 1.71 [1.57, 1.86] <0.001
HbA1c (per % point) 1.17 [1.11, 1.24] <0.001 1.11 [1.05, 1.19] <0.001
Self-reported
hypertension
1.11 [0.85, 1.44] 0.445 1.11 [0.82, 1.49] 0.494
Abbreviations: DLS, Deep Learning System; HbA1c, Glycated hemoglobin;
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Supplementary Figures
A B
Supplementary Figure S1. Histogram of the time in years between visits for (A) validation set
A and (B) validation set B.
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Supplementary Figure S2. HbA1c distribution in the two validation datasets.
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A B C
Supplementary Figure S3. Discrimination of the deep learning model for predicting incidence
of diabetic retinopathy (DR). This is the equivalent of Figure 1, but for all patients instead of only
those with the corresponding risk factors. (A,B) Receiver operating characteristic (ROC) curves
for 3-field and 1-field DLS for validation set A. (C) ROC curve for the 1-field DLS for validation
set B.
36
Supplementary Figure S4. Predicted probability of developing DR in eyes that eventually
developed DR, as a function of time before DR developed. The horizontal lines in the boxes
represent the median and quartiles; the whiskers represent 1.5 times the interquartile range;
diamonds represent outlier points outside of the whiskers. The notches in the box plot represent
confidence intervals across the median, computed using a Gaussian-based asymptotic
approximation, as implemented in Python’s matplotlib library. Note that only 17 eyes had images
7 years or longer before eventually developing DR, consistent with larger confidence intervals
for the median towards the left of the plot.
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Supplementary Figure S5. Example cases presented in Figure 4, but with three different
saliency techniques instead of one.
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Supplementary Figure S6. Effect of amount of training data on the performance of the deep
learning system (1-field). Vertical bars indicate 95% confidence intervals across the AUC as
computed on the tune set with the DeLong method, from one trained model per point.
39
Supplementary Figure S7. Differences in baseline variables and the DLS predictions between
patients with vs those without followup.
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